NovoCure (NVCR) EBT Growth (1y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -18.50% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 11.26% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -8.83% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 44.35% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 5.78% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 103.34% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 74.66% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -27.02% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 54.33% |
| 10 | NovoCure | 1.90 Bn | 1.47 Bn | 135.13 Mn | -128.61% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -128.61% |
| Dec 31, 2025 | 25.82% |
| Sep 30, 2025 | -39.09% |
| Jun 30, 2025 | -53.90% |
| Mar 31, 2025 | 4.26% |
| Dec 31, 2024 | -43.27% |
| Sep 30, 2024 | 55.24% |
| Jun 30, 2024 | 57.83% |
| Mar 31, 2024 | 38.05% |
| Dec 31, 2023 | -18.35% |
| Sep 30, 2023 | -105.93% |
| Jun 30, 2023 | -130.79% |
| Mar 31, 2023 | -1,931.01% |
| Dec 31, 2022 | -27.31% |
| Sep 30, 2022 | -122.32% |
| Jun 30, 2022 | -76.47% |
| Mar 31, 2022 | 8.01% |
| Dec 31, 2021 | -389.78% |
| Sep 30, 2021 | -195.42% |
| Jun 30, 2021 | -426.71% |
| Mar 31, 2021 | 52.97% |
| Dec 31, 2020 | 654.33% |
| Sep 30, 2020 | 749.15% |
| Jun 30, 2020 | 9,520.93% |
| Mar 31, 2020 | 31.52% |
| Dec 31, 2019 | 85.29% |
| Sep 30, 2019 | 117.01% |
| Jun 30, 2019 | 99.57% |
| Mar 31, 2019 | 51.57% |
| Dec 31, 2018 | -57.10% |
| Sep 30, 2018 | 5.35% |
| Jun 30, 2018 | 43.85% |
| Mar 31, 2018 | -10.82% |
| Dec 31, 2017 | -111.44% |
| Sep 30, 2017 | 73.48% |
| Jun 30, 2017 | 53.13% |
| Mar 31, 2017 | 51.31% |
| Dec 31, 2016 | 291.36% |
| Sep 30, 2016 | -21.59% |
| Jun 30, 2016 | -34.58% |
| Mar 31, 2016 | -44.15% |
| Dec 31, 2015 | -189.37% |
| Sep 30, 2015 | -39.48% |